A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · SEQUENTIAL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 146
- Population
- ALL · 50 Years to 89 Years
- Duration
- 2020-08-25 to 2027-02-01
- Intervention
- Ranibizumab; ABBV-RGX-314 Dose 1; ABBV-RGX-314 Dose 2; ABBV-RGX-314 Dose 3; Local Steroid; Topical Steroid; ABBV-RGX-314 Dose 4
- Comparator
- Ranibizumab control
- Outcomes measured
- Mean change from baseline in BCVA to Week 40 based on the Early Treatment Diabetic Retinopathy Study (ETDRS) score — 40…; Incidence of overall and ocular adverse events (AEs) and serious adverse events (SAEs) — 52 weeks; Vector shedding analysis in serum, urine, and tears — 52 Weeks; Proportion of participants who experience ocular inflammation following SCS ABBV-RGX-314 administration — 52 weeks; Mean change from baseline in choroidal neovascularization (CNV) lesion size and leakage area based on fluorescein angio…; Mean change from baseline in BCVA based on ETDRS score — Up to Week 80; Proportion of participants (1) gaining ≥ 15, ≥ 10, ≥ 5, or ≥ 0 letters; (2) losing ≥ 15, ≥ 10, ≥ 5, or > 0 letters (3)…; Mean change from baseline in CRT as measured by SD-OCT — Up to Week 80; Mean supplemental anti-VEGF injection annualized rate in the ABBV-RGX-314 treatment arms — Up to Week 80; Proportion of participants who have a reduction of ≥ 50% and ≥ 75% in supplemental anti-VEGF- injection annualized rate…; Proportion of participants with 0, ≤ 1, and ≤ 2 supplemental injections — Up to Week 80; Mean percent reduction in supplemental anti-VEGF injection annualized rate — Up to Week 80; Time from ABBV-RGX-314 administration to first supplemental anti-VEGF injection — 80 Weeks; Aqueous humor ABBV-RGX- 314 TP concentration over time — 52 Weeks; Mean change from baseline in serum ABBV-RGX-314 TP concentration over time — 80 Weeks
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.